[ad_1]
According to the Reuters news agency on the 4th, when the Indian Drug Administration (DCGI) approved the day before the emergency use of the vaccine ‘Cobaxine’ from the national company Barat Biotech, the industry experts and the party opposition leaders launched an offensive saying they could not be trusted.
The main reason for the criticism is that DCGI and Barat are not revealing to what extent the anti-coronavirus effect of Kobaxin is.
“How do we know how the vaccine works before the findings are published?” Said Adar Funawala, CEO of the Indian vaccine maker Serum Institute (SII).
IBS is a local company that manufactures the AstraZeneca vaccine, which has already been used in other countries, and supplies it in India under the trademark ‘Kobe Shield’.
Transparency activist Saket Cokeil said: “I don’t know what the approval was because Barat Biotech did not show enough data to prove its safety and efficacy.”
Reuters reported, citing a source, that the cobox prevention effect was found to be greater than 60% after two doses of vaccination were completed.
This is a relatively unfortunate figure considering that both Pfizer-Bioentech, Modena and the vaccines, which have been vaccinated in the United States and other countries, have been reported to be more than 90% effective.
“It can be dangerous because it’s a quick pass,” said Shashi Saruer, an opposition lawmaker and former minister in India. “It should be avoided until the trial is complete, and in the meantime, you can start vaccinating with AstraZeneca.”
DCGI also approved emergency use the day before for the Corona 19 vaccine developed jointly by the pharmaceutical company AstraZeneca and the University of Oxford in the UK.
The AstraZeneca vaccine has been tested for phase 3 in India, but Barat Biotech’s vaccine was approved for emergency use during phase 3 trials, which began in mid-November.
Authorities said in November last year that Kobaksin will be vaccinated in February or March, but the approval could speed up the supply schedule.
The Indian government emphasized endorsement of Kobaksin, developed by his own company, as a symbol of national independence.
Indian Prime Minister Narendra Modi said: “All Indians will be proud of the fact that two types of vaccines approved for emergency use have been manufactured in India. This shows our scientific aspirations to realize the dream of ‘independent India ‘”.
Before India, the United States, China, Russia, the United Kingdom and Germany approved the Corona 19 vaccine developed in their country.
[연합뉴스]
Copyright ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited
